Search for Clinical Trial Results
Lymphoma, Extranodal NK-T-Cell - 25 Studies Found
Status | Study |
Recruiting |
Study Name: Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas Condition:
Date: 2016-08-04 Interventions: |
Recruiting |
Study Name: VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT) Condition: Extranodal NK-T-Cell Lymphoma Date: 2015-09-06 Interventions:
|
Terminated |
Study Name: Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma Condition: Extranodal NK-T-CELL LYMPHOMA Date: 2016-06-09 Interventions:
|
Recruiting |
Study Name: Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients Condition: Extranodal NK-T-Cell Lymphoma, Nasal Type Date: 2017-03-09 Interventions: Combination Product: L-Asparaginase or or Pegaspargase containing chemotherapy Patients receive at least |
Recruiting |
Study Name: MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma Condition: Extranodal NK-T-Cell Lymphoma, Nasal Type Date: 2016-04-29 Interventions:
|
Recruiting |
Study Name: GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma Condition: Extranodal NK-T-Cell Lymphoma, Nasal Type Date: 2016-04-05 Interventions:
|
Recruiting |
Study Name: PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma Condition: Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Date: 2014-03-11 Interventions:
|
Completed |
Study Name: Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma Condition: Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Date: 2010-09-08 Interventions: Radiation: CCRT+MIDLE chemotherapy Patients are planned to be treated with CCRT plus MIDLE chemotherapy |
Completed |
Study Name: Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma Condition: Peripheral T/NK-cell Lymphoma Date: 2010-08-30 Interventions: Biological: KW-0761 Intravenously 8 times at 1-week intervals |
Recruiting |
Study Name: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Condition:
|